Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
DRKS00015218Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Sep 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in esophageal adenocarcinoma (EAC) comparing Adjuvant durvalumab with Adjuvant durvalumab + tremelimumab (2 arms). Primary endpoints: Safety and efficacy of adding durvalumab to standard neoadjuvant radiochemotherapy and Safety and efficacy of adjuvant durvalumab with or without tremelimumab. Started Sep 2019; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on DRKS00015218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00015218.